Company intelligence / Profile preview

Partex

Eschborn, Hessen, Germanypartex.net ↗

Ownership: Private
Development stage: Other

Overview

Partex has developed a proprietary AI-driven digital pharma platform that accelerates the identification, evaluation, repositioning, and outlicensing of biopharmaceutical assets. The company supports both internal programs—primarily first-in-class/best-in-class new chemical entities in oncology/hematology—and external partners’ pipelines by providing comprehensive analyses including target identification and indication expansion. Clinical results are not yet published for proprietary programs.

Modalities: Small molecule (NCEs)Monoclonal antibody (antibody engineering for neurodegenerative diseases)
Industry: Biotech

Partnerships

Fortress BiotechArk BiopharmaceuticalPrinceton Drug Discovery LtdSanofiParexelLupin

Beyond the preview

Go deeper on Partex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Partex.

Explore the full profile